Application of MUTIC to the exploration of gene expression data in prostate cancer

Genetics and Molecular Research

Volumn 6, Issue 4, 2007, Pages 890-900

  Goertzel, B ^a   Pennachin, C ^a   Coelho, L S ^a   Mudado, M A ^a,b  

^a Biomind LLC   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Clustering; Gene expression; Gene gene interactions; Supervised learning

Indexed keywords

ALGORITHM; CLUSTER ANALYSIS; CONFERENCE PAPER; GENE EXPRESSION; GENE INTERACTION; HUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER;

CLUSTER ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TECHNIQUES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 37349119056     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Abu-Hamad S, Sivan S and Shoshan-Barmatz V (2006). The expression level of the voltage-dependent anion channel controls life and death of the cell. Proc. Natl. Acad. Sci. USA 103: 5787-5792.
2. Ben-Dor A, Shamir R and Yakhini Z (1999). Clustering gene expression patterns. J. Comput. Biol. 6: 281-297.
3. Brown MP, Grundy WN, Lin D, Cristianini N, et al. (2000). Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc. Natl. Acad. Sci. USA 97: 262-267.
4. Cho JH, Lee D, Park JH and Lee IB (2004). Gene selection and classification from microarray data using kernel machine. FEBS Lett. 571: 93-98.
5. Chorostowska-Wynimko J, Skrzypczak-Jankun E and Jankun J (2004). Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis. Int. J. Mol. Med. 13: 759-766.
6. Christiansen JJ, Rajasekaran SA, Inge L, Cheng L, et al. (2005). N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Mol. Cancer Ther. 4: 704-714.
7. Clark DE, Errington TM, Smith JA, Frierson HF Jr, et al. (2005). The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res. 65: 3108-3116.
8. Costello LC, Franklin RB and Feng P (2005). Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 5: 143-153.
9. Dondi D, Festuccia C, Piccolella M, Bologna M, et al. (2006). GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol. Rep. 15: 393-400.
10. Dong JT (2006). Prevalent mutations in prostate cancer. J. Cell Biochem. 97: 433-447.
11. Dopazo J and Azuaje F (2005). Data analysis and visualization in genomics and proteomics. John Wiley and Sons, Chichester, West Sussex, Hoboken.
12. Dudoit S, Fridlyand J and Speed T (2002). Comparison of discrimination methods for the classification of tumors using gene expression data. J. Am. Stat. Assoc. 97: 77-87.
13. Duffy MJ and Duggan C (2004). The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37: 541-548.
14. Egland KA, Liu XF, Squires S, Nagata S, et al. (2006). High expression of a cytokeratin-associated protein in many cancers. Proc. Natl. Acad. Sci. USA 103: 5929-5934.
15. Eisen MB, Spellman PT, Brown PO and Botstein D (1998). Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95: 14863-14868.
16. Erlich S, Tal-Or P, Liebling R, Blum R, et al. (2006). Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem. Pharmacol. 72: 427-436.
17. Fischer AH, Bardarov S Jr and Jiang Z (2004). Molecular aspects of diagnostic nucleolar and nuclear envelope changes in prostate cancer. J. Cell Biochem. 91: 170-184.
18. Folini M, Brambilla C, Villa R, Gandellini P, et al. (2005). Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur. J. Cancer 41: 624-634.
19. Goertzel B, Pennachin C, de Souza Coelho L and Mudado M (2006). Identifying complex biological interactions based on categorical gene expression data. In: Proceedings of the 2006 IEEE Congress on Evolutionary Computation, Vancouver, 1434-1441.
20. Golub TR, Slonim DK, Tamayo P, Huard C, et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
21. Gonzalez-Gronow M, Gawdi G and Pizzo SV (2002). Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. Blood 99: 4562-4567.
22. Guyon I, Weston J, Barnhill S and Vapnik V (2002). Gene selection for cancer classification using support vector machines. Machine Learning 46: 389-422.
23. Holmes EH, Greene TG, Tino WT, Boynton AL, et al. (1996). Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate 7: 25-29.
24. Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, et al. (2002). The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J. 16: 1429-1431.
25. Kohli M, Fink LM, Spencer HJ and Zent CS (2002). Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul. Fibrinolysis 13: 1-5.
26. Koza JR (1992). Genetic programming: on the programming of computers by means of natural selection. MIT Press, Cambridge.
27. Kuvibidila S and Rayford W (2006). Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer. J. Lab. Clin. Med. 147: 174-181.
28. Leibowitz SB and Kantoff PW (2003). Differentiating agents and the treatment of prostate cancer: vitamin D3 and peroxisome proliferator-activated receptor gamma ligands. Semin. Oncol. 30: 698-708.
29. Llorente A, de Marco MC and Alonso MA (2004). Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J. Cell Sci. 117: 5343-5351.
30. Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, et al. (2002). Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J. Biol. Chem. 277: 10824-10833.
31. Markowetz F (2004). A bibliography on learning causal networks of gene interactions. http://www.molgen.mpg.de/~markowet/docs/network-bib.pdf or 〈http://www.molgen.mpg.de/%7Emarkowet/docs/network-bib.pdf〉. Accessed September 20, 2007.
32. Markowetz F and Spang R (2003). Reconstructing gene regulation networks from passive observations and active interventions. In: 7th Ann. Intl. Conf. Res. Comput. Molec. Biol. (Panel).
33. Moro L, Arbini AA, Marra E and Greco M (2006). Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J. Biol. Chem. 281: 22100-22107.
34. Nachman I, Regev A and Friedman N (2004). Inferring quantitative models of regulatory networks from expression data. Bioinformatics 20: i248-i256.
35. Ni Z, Lou W, Lee SO, Dhir R, et al. (2002). Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J. Urol. 167: 1859-1862.
36. Riddick AC, Shukla CJ, Pennington CJ, Bass R, et al. (2005). Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer 92: 2171-2180.
37. Ropero S, Fraga MF, Ballestar E, Hamelin R, et al. (2006). A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38: 566-569.
38. Schoenfeld AR, Apgar S, Dolios G, Wang R, et al. (2004). BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol. Cell Biol. 24: 7444-7455.
39. Schrantz N, da Silva CJ, Fowler B, Ge Q, et al. (2004). Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling. J. Biol. Chem. 279: 1922-1931.
40. Sharan R and Shamir R (2000). CLICK: a clustering algorithm with applications to gene expression analysis. Proc. Int. Conf. Intell. Syst. Mol. Biol. 8: 307-316.
41. Sharan R, Elkon R and Shamir R (2001). Cluster analysis and its applications to gene expression data. In: Ernst Schering Workshop on Bioinformatics and Genome Analysis, Springer Verlag, Berlin.
42. Shimada K, Nakamura M, Ishida E and Konishi N (2006). Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. Histol. Histopathol. 21: 415-422.
43. Singh D, Febbo PG, Ross K, Jackson DG, et al. (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
44. Skryma RN, Prevarskaya NB, Dufy-Barbe L, Odessa MF, et al. (1997). Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate 33: 112-122.
45. Sohler F, Hanisch D and Zimmer R (2004). New methods for joint analysis of biological networks and expression data. Bioinformatics 20: 1517-1521.
46. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, et al. (1998). Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol. Biol. Cell 9: 3273-3297.
47. Stephan C, Jung K, Lein M, Sinha P, et al. (2000). Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9: 1133-1147.
48. Tamayo P, Slonim D, Mesirov J, Zhu Q, et al. (1999). Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc. Natl. Acad. Sci. USA 96: 2907-2912.
49. Tan AC and Gilbert D (2003). Ensemble machine learning on gene expression data for cancer classification. Appl. Bioinformatics 2: S75-S83.
50. Van Coppenolle F, Skryma R, Ouadid-Ahidouch H, Slomianny C, et al. (2004). Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation. Biochem. J. 377: 569-578.
51. Ventura S, Pennefather J and Mitchelson F (2002). Cholinergic innervation and function in the prostate gland. Pharmacol. Ther. 94: 93-112.
52. Vert JP and Kanehisa M (2003). Extracting active pathways from gene expression data. Bioinformatics 19: ii238-ii244.
53. Wang C, McCarty IM, Balazs L, Li Y, et al. (2002). Immunohistological detection of BRAF25 in human prostate tumor and cancer specimens. Biochem. Biophys. Res. Commun. 295: 136-141.
54. Wang J, Lundqvist M, Carlsson L, Nilsson O, et al. (2001). Prostasome-like granules from the PC-3 prostate cancer cell line increase the motility of washed human spermatozoa and adhere to the sperm. Eur. J. Obstet. Gynecol. Reprod. Biol. 96: 88-97.
55. Welsh JB, Sapinoso LM, Su AI, Kern SG, et al. (2001). Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61: 5974-5978.
56. Yang J, Wu HF, Zhang W, Gu M, et al. (2006). Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility. Front. Biosci. 11: 2052-2060.
57. Yano A, Fujii Y, Iwai A, Kawakami S, et al. (2006). Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin. Cancer Res. 12: 3003-3009.
58. Yeung CH, Perez-Sanchez F, Soler C, Poser D, et al. (1997). Maturation of human spermatozoa (from selected epididymides of prostatic carcinoma patients) with respect to their morphology and ability to undergo the acrosome reaction. Hum. Reprod. Update 3: 205-213.
59. Zerbini LF, Wang Y, Correa RG, Cho JY, et al. (2005). Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 4: 1247-1253.